Maxillofacial Plastic and Reconstructive Surgery

  • Volume 41
  • /
  • Pages.11.1-11.6
  • /
  • 2019
  • /
  • 2288-8101(pISSN)
  • /
  • 2288-8586(eISSN)
Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of bisphosphonate on temporomandibular joint in osteopenia-induced rats by botulinum toxin A injection on masticatory muscle: a preliminary study

  • Kim, Jae-Young (Department of Oral and Maxillofacial Surgery, Gangnam Severance Hospital, Yonsei University College of Dentistry) ;
  • Kim, Dae-Hoon (Department of Oral and Maxillofacial Surgery, Gangnam Severance Hospital, Yonsei University College of Dentistry) ;
  • Jang, Hyo-Won (Department of Oral and Maxillofacial Surgery, Gangnam Severance Hospital, Yonsei University College of Dentistry) ;
  • Park, Kwang-Ho (Department of Oral and Maxillofacial Surgery, Gangnam Severance Hospital, Yonsei University College of Dentistry) ;
  • Huh, Jong-Ki (Department of Oral and Maxillofacial Surgery, Gangnam Severance Hospital, Yonsei University College of Dentistry)
  • Received : 2019.01.01
  • Accepted : 2019.02.15
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Botulinum toxin injection on the masticatory muscle induces the osteopenic condition on the ipsilateral condyle. Bisphosphonate suppresses bone resorption and is used to treat osteopenic or osteoporotic condition. This study aimed to evaluate the effect of bisphosphonate administration on prevention of condylar resorption and botulinum toxin A-induced disuse osteopenia in rats. Results: The volume of the condyle and bone volume/tissue volume (BV/TV, %) showed a strong tendency towards statistical significance (p = 0.052 and 0.058). Trabecular thickness (Tb.Th, mm) and trabecular number (Tb.N, 1/mm) were significantly smaller in the Botox group than in the other groups (p < 0.05). The volume of the condyle and BV/TV in the bisphosphonate 100 and bisphosphonate 200 groups showed similar values when compared with the control group. Conclusion: Bisphosphonate administration after botulinum toxin A injection in the masticatory muscles appears to prevent condyle resorption and botulinum toxin-induced disuse osteopenia in rats.

Keywords

References

  1. Matthys T, Ho Dang HA, Rafferty KL, Herring SW (2015) Bone and cartilage changes in rabbit mandibular condyles after 1 injection of botulinum toxin. Am J Orthod Dentofac Orthop 148:999-1009 https://doi.org/10.1016/j.ajodo.2015.05.034
  2. Davletov B, Bajohrs M, Binz T (2005) Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci 28:446-452 https://doi.org/10.1016/j.tins.2005.06.001
  3. Kim NH, Park RH, Park JB (2010) Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg 125:1693-1705 https://doi.org/10.1097/PRS.0b013e3181d0ad03
  4. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P (2011) Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain 152:1988-1996 https://doi.org/10.1016/j.pain.2011.03.036
  5. Tsai CY, Huang RY, Lee CM, Hsiao WT, Yang LY (2010) Morphologic and bony structural changes in the mandible after a unilateral injection of botulinum neurotoxin in adult rats. J Oral Maxillofac Surg 68:1081-1087 https://doi.org/10.1016/j.joms.2009.12.009
  6. Rafferty KL, Liu ZJ, Ye W et al (2012) Botulinum toxin in masticatory muscles: short- and long-term effects on muscle, bone, and craniofacial function in adult rabbits. Bone 50:651-662 https://doi.org/10.1016/j.bone.2011.11.015
  7. Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032-1045 https://doi.org/10.4065/83.9.1032
  8. Khosla S, Bilezikian JP, Dempster DW et al (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97:2272-2282 https://doi.org/10.1210/jc.2012-1027
  9. Kun-Darbois JD, Libouban H, Chappard D (2015) Botulinum toxin in masticatory muscles of the adult rat induces bone loss at the condyle and alveolar regions of the mandible associated with a bone proliferation at a muscle enthesis. Bone 77:75-82 https://doi.org/10.1016/j.bone.2015.03.023
  10. Raphael KG, Tadinada A, Bradshaw JM et al (2014) Osteopenic consequences of botulinum toxin injections in the masticatory muscles: a pilot study. J Oral Rehabil 41:555-563 https://doi.org/10.1111/joor.12180
  11. Aziz J, Awal D, Ayliffe P (2017) Resorption of the mandibular condyle after injections of botulinum toxin A. Br J Oral Maxillofac Surg 55:987-988 https://doi.org/10.1016/j.bjoms.2017.09.010
  12. Seok H, Kim SG, Kim MK, Jang I, Ahn J (2018) Effect of the masseter muscle injection of botulinum toxin A on the mandibular bone growth of developmental rats. Maxillofac Plast Reconstr Surg 40:5 https://doi.org/10.1186/s40902-018-0146-4
  13. Allen MR (2008) Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment. Expert Opin Drug Metab Toxicol 4:1371-1378 https://doi.org/10.1517/17425255.4.11.1371
  14. Shirai T, Kobayashi M, Nishitani K et al (2011) Chondroprotective effect of alendronate in a rabbit model of osteoarthritis. J Orthop Res 29:1572-1577 https://doi.org/10.1002/jor.21394
  15. Zhu S, Chen K, Lan Y, Zhang N, Jiang R, Hu J (2013) Alendronate protects against articular cartilage erosion by inhibiting subchondral bone loss in ovariectomized rats. Bone 53:340-349 https://doi.org/10.1016/j.bone.2012.12.044
  16. Chen K, Zhang N, Ding L, Zhang W, Hu J, Zhu S (2014) Early intra-articular injection of alendronate reduces cartilage changes and subchondral bone loss in rat temporomandibular joints after ovariectomy. Int J Oral Maxillofac Surg 43:996-1004 https://doi.org/10.1016/j.ijom.2014.04.003
  17. Kim JW, Cha IH, Kim SJ, Kim MR (2016) Biomarkers for bisphosphonaterelated osteonecrosis of the jaw. Clin Implant Dent Relat Res 18:281-291 https://doi.org/10.1111/cid.12297
  18. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 https://doi.org/10.1056/NEJMoa067312
  19. Vegger JB, Bruel A, Thomsen JS (2018) Zoledronic acid prevents disuse osteopenia and augments gene expression of osteoclastic differentiation markers in mice. J Musculoskelet Neuronal Interact 18:165-175